Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1839, Issue 9, 2014, Pages 858-865

  Tao, Tao ^a   Liu, Dachuang ^a   Liu, Chunhui ^a   Xu, Bin ^a   Chen, Shuqiu ^a   Yin, Yu ^b   Ang, Lin ^c   Huang, Yeqing ^a   Zhang, Xiaowen ^a   Chen, Ming ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c The Second People's Hospital of Hefei   (China)

Author keywords

Cell cycle; E2F3; EZH2; MiR 200c; Prostate cancer

Indexed keywords

MICRORNA 200C; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR EZH2;

3' UNTRANSLATED REGION; ARTICLE; AUTOREGULATION; BINDING SITE; BIOINFORMATICS; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE PROGRESSION; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; EPIGENETIC REPRESSION; FEEDBACK SYSTEM; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUCIFERASE ASSAY; MALE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

CELL CYCLE; E2F3; EZH2; MIR-200C; PROSTATE CANCER;

CELL LINE, TUMOR; CELL PROLIFERATION; E2F3 TRANSCRIPTION FACTOR; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; MALE; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; PROSTATIC NEOPLASMS;

EID: 84904726856     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.07.001     Document Type: Article

References (28)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Yang Y.A., Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell 2013, 4:331-341.
3. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
4. Kim J., Yu J. Interrogating genomic and epigenomic data to understand prostate cancer. Biochim. Biophys. Acta 2012, 1825:186-196.
5. Chang C.J., Hung M.C. The role of EZH2 in tumour progression. Br. J. Cancer 2012, 106:243-247.
6. Lai E.C. MicroRNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 2002, 30:363-364.
7. Zhu C., Li J., Ding Q., Cheng G., Zhou H., Tao L., Cai H., Li P., Cao Q., Ju X., Meng X., Qin C., Hua L., Shao P., Yin C. MiR-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. Prostate 2013, 73:1082-1089.
8. Liu D., Tao T., Xu B., Chen S., Liu C., Zhang L., Lu K., Huang Y., Jiang L., Zhang X., Huang X., Zhang L., Han C., Chen M. MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6 (STAT6). Biochem. Biophys. Res. Commun. 2014, 445:151-156.
9. Xu B., Wang N., Wang X., Tong N., Shao N., Tao J., Li P., Niu X., Feng N., Zhang L., Hua L., Wang Z., Chen M. MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate 2012, 72:1171-1178.
10. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
11. Cao Q., Mani R.S., Ateeq B., Dhanasekaran S.M., Asangani I.A., Prensner J.R., Kim J.H., Brenner J.C., Jing X., Cao X., Wang R., Li Y., Dahiya A., Wang L., Pandhi M., Lonigro R.J., Wu Y.M., Tomlins S.A., Palanisamy N., Qin Z., Yu J., Maher C.A., Varambally S., Chinnaiyan A.M. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 2011, 20:187-199.
12. Mongroo P.S., Rustgi A.K. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol. Ther. 2010, 10:219-222.
13. Pang Y., Young C.Y., Yuan H. MicroRNAs and prostate cancer. Acta Biochim. Biophys. Sin. 2010, 42:363-369.
14. Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T., Mason M., Matveev V., Wiegel T., Zattoni F., Mottet N. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2014, 65:467-479.
15. Shi Z.M., Wang X.F., Qian X., Tao T., Wang L., Chen Q.D., Wang X.R., Cao L., Wang Y.Y., Zhang J.X., Jiang T., Kang C.S., Jiang B.H., Liu N., You Y.P. MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas. RNA 2013, 19:552-560.
16. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323-5335.
17. Tao T., Wang Y., Luo H., Yao L., Wang L., Wang J., Yan W., Zhang J., Wang H., Shi Y., Yin Y., Jiang T., Kang C., Liu N., You Y. Involvement of FOS-mediated miR-181b/miR-21 signalling in the progression of malignant gliomas. Eur. J. Cancer 2013, 49:3055-3063.
18. Aldiri I., Vetter M.L. PRC2 during vertebrate organogenesis: a complex in transition. Dev. Biol. 2012, 367:91-99.
19. Cao Q., Yu J., Dhanasekaran S.M., Kim J.H., Mani R.S., Tomlins S.A., Mehra R., Laxman B., Cao X., Yu J., Kleer C.G., Varambally S., Chinnaiyan A.M. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284.
20. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11606-11611.
21. Yu J., Cao Q., Mehra R., Laxman B., Yu J., Tomlins S.A., Creighton C.J., Dhanasekaran S.M., Shen R., Chen G., Morris D.S., Marquez V.E., Shah R.B., Ghosh D., Varambally S., Chinnaiyan A.M. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell 2007, 12:419-431.
22. Min J., Zaslavsky A., Fedele G., McLaughlin S.K., Reczek E.E., De Raedt T., Guney I., Strochlic D.E., Macconaill L.E., Beroukhim R., Bronson R.T., Ryeom S., Hahn W.C., Loda M., Cichowski K. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat. Med. 2010, 16:286-294.
23. Bracken A.P., Helin K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 2009, 9:773-784.
24. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
25. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2257-2261.
26. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67:6130-6135.
27. Ozen M., Creighton C.J., Ozdemir M., Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788-1793.
28. Zhu W., Giangrande P.H., Nevins J.R. E2Fs link the control of G1/S and G2/M transcription. EMBO J. 2004, 23:4615-4626.